We are live on ! Find out more
MG

Michael Gelband ExodusPoint Capital Management

AUM $15.5B
1-Year Est. Return 38.81%
 

Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.

This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+38.81%
3 Year Est. Return
+110.53%
5 Year Est. Return
+124.16%
10 Year Est. Return
AUM
$15.5B
AUM Growth
+$2.94B
Cap. Flow
+$1.45B
Cap. Flow %
9.35%
Top 10 Hldgs %
30.63%
Holding
2,230
New
735
Increased
384
Reduced
378
Closed
720

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$614M
2
AAPL icon
Apple
AAPL
+$443M
3
BLD
TopBuild
BLD
+$391M
4
SPCX
SpaceX
SPCX
+$329M
5
PEN icon
Penumbra
PEN
+$203M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$1.96B
2
NVDA icon
NVIDIA
NVDA
+$425M
3
SNDK
Sandisk
SNDK
+$88M
4
SO icon
Southern Company
SO
+$80.6M
5
PPL
PPL Corp
PPL
+$74.1M

Sector Composition

Rank Sector Weight
1 Technology 16.4%
2 Industrials 13.64%
3 Consumer Discretionary 9.5%
4 Healthcare 7.9%
5 Financials 5.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HOLX
1776
PUT
DELISTED
Hologic
HOLX
-58,300
Closed -$4.41M
HOMB icon
1777
Home BancShares
HOMB
$6.06B
-102,994
Closed -$2.77M
HON icon
1778
Honeywell
HON
$68.4B
-188,496
Closed -$42.6M
HOOD icon
1779
Robinhood
HOOD
$97.2B
-59,463
Closed -$4.12M
HPQ icon
1780
HP
HPQ
$27.2B
-584,750
Closed -$11.2M
HQY icon
1781
HealthEquity
HQY
$8.81B
-54,855
Closed -$4.58M
HRMY icon
1782
Harmony Biosciences
HRMY
$2.22B
-64,197
Closed -$1.8M
HSY icon
1783
Hershey
HSY
$37.5B
-3,205
Closed -$666K
HTGC icon
1784
Hercules Capital
HTGC
$3.21B
-24,686
Closed -$365K
HTZ icon
1785
Hertz
HTZ
$802M
-343,339
Closed -$1.58M
HUBG icon
1786
HUB Group
HUBG
$2.49B
-143,320
Closed -$5.17M
HXL icon
1787
Hexcel
HXL
$7.1B
-28,791
Closed -$2.33M
IART icon
1788
Integra LifeSciences
IART
$1.3B
-242,399
Closed -$2.28M
IAUX
1789
i-80 Gold Corp
IAUX
$1.57B
-27,490
Closed -$41.8K
IBCP icon
1790
Independent Bank Corp
IBCP
$824M
-26,071
Closed -$868K
IBEX icon
1791
IBEX
IBEX
$490M
-22,347
Closed -$599K
ICFI icon
1792
ICF International
ICFI
$1.6B
-91,476
Closed -$5.97M
IESC icon
1793
IES Holdings
IESC
$27.3B
-3,180
Closed -$1.52M
IEX icon
1794
IDEX
IEX
$17.3B
-108,973
Closed -$20.7M
IFF icon
1795
International Flavors & Fragrances
IFF
$21.5B
-8,144
Closed -$591K
IHS icon
1796
IHS Holding
IHS
$2.84B
-34,575
Closed -$285K
ILF icon
1797
iShares Latin America 40 ETF
ILF
$3.9B
-4,300
Closed -$153K
IMAX icon
1798
IMAX
IMAX
$2.89B
-34,528
Closed -$1.31M
IMCR icon
1799
Immunocore
IMCR
$1.9B
-40,279
Closed -$1.21M
IMNM icon
1800
Immunome
IMNM
$3.24B
-115,370
Closed -$2.52M

Similar funds

Michael Gelband's Q2 2026 Portfolio in Review

As of Q2 2026, Michael Gelband held 2,230 positions worth $15.5B, up 23% from $12.6B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Michael Gelband deployed $1.45B of net new capital in Q2 2026, opening 735 new positions and adding to 384 existing holdings. Its largest new stake was SpaceX: 1,938,935 shares worth $331M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Tesla, an estimated $1.96B trimmed.

  • Michael Gelband's largest Q2 2026 buy was SpaceX: 1,938,935 shares worth $331M.
  • Michael Gelband added most to Amazon in Q2 2026, an estimated $614M increase.
  • Michael Gelband's biggest Q2 2026 reduction was Tesla, cutting an estimated $1.96B.
  • Michael Gelband fully exited Southern Company in Q2 2026, selling an estimated $80.6M.
  • Michael Gelband's ten largest holdings make up 31% of its $15.5B portfolio in Q2 2026.
  • Michael Gelband opened 735 new positions and closed 720 in Q2 2026.
  • Michael Gelband's portfolio value rose 23% quarter-over-quarter to $15.5B.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.